Thus, GD3 is probably able to recruit mutated receptor tyrosine kinases to glycolipid-enriched microdomain GEM/rafts and to activate these receptor tyrosine kinases in a ligand-independent manner, leading to the increased malignant properties of gliomas. Here, NTRK1 is linked to central nervous system cancer.